Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/14/2023* 08:30 EST Earnings Call Q4 2022 -- -- --
03/14/2023* -- Results Q4 2022 -- -0.26 --
11/08/2022 -- Results Q3 2022 -0.04 -0.27 85.19%
11/08/2022 08:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 08:00 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.05 -0.27 81.25%
05/09/2022 08:00 EST Earnings Call Q1 2022 -- -- --
05/09/2022 -- Results Q1 2022 -0.30 -0.26 -14.29%
*Estimated Date/Time

Earnings

Next Report Date 03/14/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/08/2022
Beat/Miss Upgrade
Return Since 5.77%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
URL https://www.adaptimmune.com
Investor Relations URL https://www.adaptimmune.com/investors-and-media
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Mar. 14, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
-66.42%
64.94%
-13.92%
-79.13%
349.2%
-30.43%
-41.33%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
-69.79%
-51.45%
-38.49%
-63.74%
11.46%
5.71%
-18.92%
-62.19%
--
--
--
--
-59.81%
-32.27%
-41.95%
-51.83%
--
--
--
-18.71%
-40.41%
21.74%
-4.00%
87.65%
--
--
--
--
--
9.15%
-55.31%
-52.05%
As of November 25, 2022.

Profile

Edit
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
URL https://www.adaptimmune.com
Investor Relations URL https://www.adaptimmune.com/investors-and-media
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Mar. 14, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
QQQS 27255.00 USD 0.66%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ADAP Tweets